

Genovis Q2 2023 - Strong growth and expanding EBIT margin

Redeye continues to see potential for stellar growth ahead for Genovis following its Q2 2023 report, which showcased 40% sales growth coupled with 20% EBIT margins. In this report we discuss the report, recent developments and slightly upwards adjust our base case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Genovis Q2 2023 - Strong growth and expanding EBIT margin](#)